Silver Book Fact

Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.

Provenzano G, Duttagupta S, McRae T, Mastey V, et al. Delays in Nursing Home Placement for Patients with Alzheimer s Disease Associated with Donepezil May Have Care Cost Savings Implications. Value in Health. 2001; 4(2): 158. https://www.valueinhealthjournal.com/article/S1098-3015(11)71392-4/abstract

Reference

Title
Delays in Nursing Home Placement for Patients with Alzheimer s Disease Associated with Donepezil May Have Care Cost Savings Implications
Publication
Value in Health
Publication Date
2001
Authors
Provenzano G, Duttagupta S, McRae T, Mastey V, et al
Volume & Issue
Volume 4, Issue 2
Pages
158
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.  
  • Recent studies suggest that a low-fat diet which is rich in fruits and vegetables may support brain health. Other studies suggest that remaining socially active and intellectually engaged may also…  
  • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development is to treat Alzheimer’s disease. The medicine inhibits plaque formation and blocks the…  
  • Impact of Slowed Progression on Severe Stage, Americans Age 65 and Older with Alzheimer’s, 2010-2050  
  • Medicines Allow Patients to Remain Independent Longer: New Alzheimer’s medicine delays need for costly home care